CalciMedica stock analysis
Want to see CALC full AI Analyst Report?
CalciMedica (CALC) Stock Price & Analysis
CALC Stock Chart & Stats
- Day’s Range
- $1.19 - $1.31
- 52-Week Range
- $1.00 - $36.00
- Previous Close
- $1.22
- Volume
- N/A
- Average Volume (3M)
- 77.92K
- Market Cap
- $8.34M
- Enterprise Value
- $4.33M
- Total Cash (Recent Filing)
- $13.77M
- Total Debt (Recent Filing)
- $0
- Price to Earnings (P/E)
- ―
- Beta
- 0.13
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- -0.63
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
The absence of debt reduces near-term interest and refinancing pressure, while positive equity provides some balance-sheet support for ongoing development. This gives CalciMedica greater financial flexibility than a similarly loss-making biotech carrying material leverage.
Nasdaq Compliance Restored
Restored Nasdaq compliance removes the immediate listing deficiency and reduces operational disruption associated with potential delisting. Maintaining an exchange listing can preserve access to public capital markets and support the company’s ability to finance clinical development.
Losses Have Narrowed
Narrower losses indicate some improvement in the company’s cost or spending profile, even though profitability remains distant. If sustained, this trend could extend the cash runway and reduce the amount of external funding required before potential product revenue.
Bears Say
No Commercial Revenue
The absence of commercial revenue leaves CalciMedica dependent on successful clinical and regulatory progress before it can become self-funding. Continued operating losses also make future earnings uncertain and increase the financial consequences of delays or unsuccessful development.
Substantial Cash Burn
Persistent negative operating and free cash flow means the business is consuming capital rather than generating funds internally. This limits financial durability and requires continued access to financing, particularly while clinical development and regulatory activities remain ongoing.
Equity Funding And Dilution Risk
The planned equity-raising capacity can support liquidity and corporate activities, but issuing shares or share-linked securities may dilute existing ownership. Reliance on these financings also underscores the company’s dependence on external capital while revenue remains absent.
CalciMedica News
CalciMedica, FDA alignment de-risks regulatory path, says H.C. Wainwright
FDA alignment on CalciMedica’s (CALC) acute pancreatitis program for Auxora de-risks the regulatory path, validating Phase 2b endpoint selection and patient enrichment strategy while advancing a potential registration pathway in
CALC FAQ
What was CalciMedica’s price range in the past 12 months?
What is CalciMedica’s market cap?
When is CalciMedica’s upcoming earnings report date?
How were CalciMedica’s earnings last quarter?
Is CalciMedica overvalued?
Does CalciMedica pay dividends?
What is CalciMedica’s EPS estimate?
How many shares outstanding does CalciMedica have?
What happened to CalciMedica’s price movement after its last earnings report?
Which hedge fund is a major shareholder of CalciMedica?
What is the TipRanks Smart Score and how is it calculated?
Company Description
CalciMedica
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- A. Rachel Leheny
- Employees
- 16
- Website
- www.calcimedica.com
- Address
- 505 Coast Boulevard South, La Jolla, CA, 92037, US
CalciMedica (CALC) Earnings & Revenues
CALC Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 4 | 15 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 0 | 0 | 12 |











